68 Ga-CXCR4-targeted PET/CT Outperforms 18 F-FDG PET/CT in FLT3-mutated AML M1 With Granulocytic Sarcoma : Theranostic Insights.

68 Ga-CXCR4 PET/CT was performed in a patient with acute myeloid leukemia (AML) and granulocytic sarcoma in the left cervical region, who had previously undergone 18 F-FDG PET/CT. Compared with 18 F-FDG PET/CT, 68 Ga-CXCR4 PET/CT revealed a greater number of malignant lymph nodes with more intense uptake in both supradiaphragmatic and infradiaphragmatic regions. Furthermore, markedly increased radiotracer uptake was observed in the bone marrow and spleen compared with FDG. This case underscores the superior sensitivity of 68 Ga-CXCR4 PET/CT in detecting AML infiltration and supports further investigation of CXCR4-targeted imaging and therapeutic approaches in high-risk AML.